Zahn
Alain Zahn, Zurich CH
Patent application number | Description | Published |
---|---|---|
20120045652 | COMPOSITION CONTAINING A SURFACE-DEACTIVATED POLYISOCYANATE AND CURING IN TWO STAGES - Single-component compositions are disclosed, which can be cured in two stages, wherein in the first curing stage, compositions pre-cured by means of moisture and having in particular plastic properties are formed, and wherein in the second curing stage, compositions cured by means of heat and having in particular elastic properties are formed. The two-stage compositions are suitable in particular as adhesives and have the great advantage that thanks to said two-stage compositions, an adhesive can be applied to a substrate, said adhesive cures by means of moisture in such a way that it can be handled and stored without problems, and said adhesive can be cured easily in an adhering step by means of heat only when needed. | 02-23-2012 |
Dirk Zahn, Singapore SG
Patent application number | Description | Published |
---|---|---|
20100311077 | Use of GPR100 Receptor in Diabetes and Obesity Regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto. | 12-09-2010 |
Dirk Zahn, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20080269118 | Use of Gpr100 receptor in diabetes and obesity regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto. | 10-30-2008 |
Fritz Helmut Zahn, Geldrop NL
Patent application number | Description | Published |
---|---|---|
20140355239 | Beam shaping light emitting module - There is provided a light emitting module ( | 12-04-2014 |
Hans Zahn, Vancouver CA
Patent application number | Description | Published |
---|---|---|
20140208832 | Methods and Apparatus for Flow-Controlled Wetting - Methods of determining a first position at which a dispersed phase droplet wets a surface of a channel are provided herein. The methods include immersing the dispersed phase droplet in a continuous phase fluid, wherein the continuous phase fluid is immiscible with the dispersed phase droplet, subsequently flowing the dispersed phase droplet in the continuous phase through the channel at a dispersed phase droplet velocity, wherein the dispersed phase droplet is separated from the surface by a film of the continuous phase fluid having a film thickness, and reducing the film thickness to rupture the film at the first position, wherein the droplet wets the surface at the first position. | 07-31-2014 |
Michael Zahn, Singapore SG
Patent application number | Description | Published |
---|---|---|
20160001545 | STENCILS - A stencil for printing a pattern of deposits on a substrate, wherein the stencil comprises an electroformed metal sheet which has a first layer which includes an apertured region through which a printing medium is applied in a printing operation, and a second layer which overlies a substrate to be printed and includes a plurality of apertures, wherein the apertures of the second layer extend across and beyond the apertured region in the first layer, whereby the second layer includes a plurality of through apertures in registration with the apertured region of the first layer, each having a pattern corresponding to that to be printed on the substrate, and a plurality of blind apertures disposed adjacent and outwardly of the apertured region in the first layer. | 01-07-2016 |
Ralph Zahn, Zürich CH
Patent application number | Description | Published |
---|---|---|
20090258419 | METHOD FOR REMOVING PRION PROTEIN - The present invention relates to a method for removing prion PrP | 10-15-2009 |
Ralph Zahn, Zurich CH
Patent application number | Description | Published |
---|---|---|
20090081345 | Identification of Prion Proteins in Milk - The present invention relates to the use of milk or a derivative thereof for identifying prion proteins, preferably PrP | 03-26-2009 |
20090258419 | METHOD FOR REMOVING PRION PROTEIN - The present invention relates to a method for removing prion PrP | 10-15-2009 |
20110009604 | Method for Concentrating, Purifying and Removing Prion Protein - The present invention relates to a method for concentrating and/or purifying prion PrP | 01-13-2011 |
Stefan Zahn, Steulose DK
Patent application number | Description | Published |
---|---|---|
20160046712 | KIR-BINDING AGENTS AND METHODS OF USE THEREOF - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 02-18-2016 |
Stefan Zahn, Ballerup DK
Patent application number | Description | Published |
---|---|---|
20080305117 | Kir-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 12-11-2008 |
20090075340 | Kir-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 03-19-2009 |
20090081240 | Human Anti-Kir Antibodies - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 03-26-2009 |
20130143269 | KIR-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 06-06-2013 |
20130164299 | LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES - The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis. | 06-27-2013 |
20160024215 | LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES - The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis. | 01-28-2016 |
Stefan Zahn, Bagsvaerd DK
Patent application number | Description | Published |
---|---|---|
20120208237 | HUMAN ANTI-KIR ANTIBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 08-16-2012 |
20150191547 | HUMAN ANTI-KIR ANTIBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 07-09-2015 |
20150344576 | HUMAN ANTI-KIR ANTIBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 12-03-2015 |
Stefan Zahn, Stenloese DK
Patent application number | Description | Published |
---|---|---|
20130004514 | THERAPEUTIC ANTIBODIES - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 01-03-2013 |
20130295116 | THERAPEUTIC ANTIBODIES - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 11-07-2013 |
20150044231 | Therapeutic Antibodies - The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders. | 02-12-2015 |
Stefan Zahn, Bagsvaers DK
Patent application number | Description | Published |
---|---|---|
20130287770 | HUMAN ANTI-KIR ANITBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 10-31-2013 |
Stephan Karl Zahn, Vienna AT
Patent application number | Description | Published |
---|---|---|
20090149438 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 06-11-2009 |
20090163465 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 06-25-2009 |
20090163467 | New compounds - The present invention encompasses compounds of general formula (1) | 06-25-2009 |
20100144706 | Compounds - The present invention encompasses compounds of general formula (1) wherein R | 06-10-2010 |
20100184747 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER - The present invention encompasses compounds of general formula (1) wherein R | 07-22-2010 |
20100222331 | NEW COMPOUNDS - The present invention encompasses compounds of general Formula (1) wherein R | 09-02-2010 |
20110086842 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 04-14-2011 |
20110251174 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS - The present invention encompasses compounds of general formula (1) | 10-13-2011 |
20120094975 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS - The present invention encompasses compounds of general formula (1) wherein the groups R | 04-19-2012 |
20120270859 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER - The present invention encompasses compounds of general formula (1) | 10-25-2012 |
20120329771 | BENZYLIC OXINDOLE PYRIMIDINES - The present invention encompasses compounds of general formula (I) | 12-27-2012 |
20130281429 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS - The present invention encompasses compounds of general formula (1) | 10-24-2013 |
20140018372 | CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE - A crystalline form of 3-{3-[1-(4-Dimethylaminomethyl-phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl}-propynoic acid ethylamide. | 01-16-2014 |
20140018405 | Anticancer Compounds - The invention describes dual Aurora kinase/MEK inhibitors and their use in therapy. | 01-16-2014 |
Thomas Christian Zahn, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20100027588 | Content Transfer - Content transfer between nodes in a communications network is required in many situations. For example, between fixed nodes in a data center, between a fixed node such as a base station and a mobile node such as a mobile telephone and between mobile nodes themselves such as personal digital assistants. In an embodiment a content transfer process for use between nodes where one node knows the size of content to be transferred is described. For example, a file is divided into blocks to be sent between the nodes. A node receiving a block keeps a record of the received blocks and sends that record to the sending node at certain times. By controlling the times at which the records are sent the number of messages that need to be sent to transfer the records is low and the blocks are transferred in an efficient manner. | 02-04-2010 |
20100030840 | Content Discovery and Transfer Between Mobile Communications Nodes - Content discovery and content transfer between mobile communications nodes is often required, for example, to synchronize maps, traffic hot spot information and the like for vehicle mounted satellite navigation devices, pedestrian hand-held personal digital assistants and other mobile communications nodes. In an embodiment, content discovery processes using data structures designed in particular ways and sent using a single packet enable nodes to identify files to be transferred whilst keeping overheads down. In an embodiment a first and a second data structure are used, each being formed from slightly different information about a subset of the files to be synchronized. In another embodiment a single tree-based data structure is used. A process for transferring data between two mobile communications nodes is also described. | 02-04-2010 |
20120072478 | Content Discovery and Transfer Between Mobile Communications Nodes - Content discovery and content transfer between mobile communications nodes is often required, for example, to synchronize maps, traffic hot spot information and the like for vehicle mounted satellite navigation devices, pedestrian hand-held personal digital assistants and other mobile communications nodes. In an embodiment, content discovery processes using a tree-based data structure for transferring data between two mobile communication nodes is described. | 03-22-2012 |